Research Analysts Offer Predictions for Edwards Lifesciences Corp’s FY2021 Earnings (EW)

Edwards Lifesciences Corp (NYSE:EW) – Analysts at Svb Leerink lowered their FY2021 earnings per share estimates for Edwards Lifesciences in a note issued to investors on Friday, April 12th. Svb Leerink analyst D. Antalffy now forecasts that the medical research company will post earnings per share of $6.26 for the year, down from their previous forecast of $6.44. Svb Leerink also issued estimates for Edwards Lifesciences’ FY2022 earnings at $6.96 EPS and FY2023 earnings at $7.70 EPS.

A number of other analysts have also recently weighed in on EW. Credit Suisse Group restated an “outperform” rating and issued a $221.00 price target (up from $189.00) on shares of Edwards Lifesciences in a report on Monday. Barclays raised their price target on shares of Edwards Lifesciences from $150.00 to $160.00 and gave the company an “underweight” rating in a report on Monday, March 25th. Canaccord Genuity restated a “buy” rating and issued a $215.00 price target (up from $190.00) on shares of Edwards Lifesciences in a report on Monday, March 18th. Stifel Nicolaus restated a “buy” rating and issued a $190.00 price target on shares of Edwards Lifesciences in a report on Sunday, February 3rd. Finally, BMO Capital Markets raised their price target on shares of Edwards Lifesciences to $204.00 and gave the company an “outperform” rating in a report on Friday, March 22nd. Two investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and thirteen have given a buy rating to the stock. The company has an average rating of “Buy” and an average price target of $182.29.



NYSE:EW opened at $189.23 on Monday. Edwards Lifesciences has a fifty-two week low of $123.00 and a fifty-two week high of $197.86. The stock has a market capitalization of $40.04 billion, a PE ratio of 40.26, a PEG ratio of 2.46 and a beta of 0.91. The company has a current ratio of 2.61, a quick ratio of 1.92 and a debt-to-equity ratio of 0.19.

Edwards Lifesciences (NYSE:EW) last issued its earnings results on Thursday, January 31st. The medical research company reported $1.17 earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of $1.17. Edwards Lifesciences had a net margin of 19.40% and a return on equity of 31.09%. The company had revenue of $977.70 million for the quarter, compared to analysts’ expectations of $973.72 million. During the same period in the prior year, the business earned $0.94 EPS.

In related news, VP Jean-Luc M. Lemercier sold 4,186 shares of Edwards Lifesciences stock in a transaction that occurred on Tuesday, April 9th. The shares were sold at an average price of $188.23, for a total value of $787,930.78. Following the completion of the sale, the vice president now directly owns 44,596 shares in the company, valued at approximately $8,394,305.08. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Larry L. Wood sold 6,716 shares of Edwards Lifesciences stock in a transaction that occurred on Monday, April 1st. The stock was sold at an average price of $192.34, for a total transaction of $1,291,755.44. Following the completion of the sale, the vice president now owns 122,495 shares of the company’s stock, valued at $23,560,688.30. The disclosure for this sale can be found here. Insiders sold a total of 112,854 shares of company stock valued at $19,838,296 over the last quarter. 1.84% of the stock is owned by company insiders.

A number of hedge funds have recently added to or reduced their stakes in the stock. Capital Insight Partners LLC raised its position in Edwards Lifesciences by 0.5% during the 1st quarter. Capital Insight Partners LLC now owns 11,010 shares of the medical research company’s stock worth $2,107,000 after buying an additional 53 shares during the last quarter. Cetera Advisor Networks LLC raised its position in Edwards Lifesciences by 3.8% during the 4th quarter. Cetera Advisor Networks LLC now owns 1,573 shares of the medical research company’s stock worth $242,000 after buying an additional 57 shares during the last quarter. Kentucky Retirement Systems raised its position in Edwards Lifesciences by 0.7% during the 4th quarter. Kentucky Retirement Systems now owns 9,093 shares of the medical research company’s stock worth $1,393,000 after buying an additional 60 shares during the last quarter. Parallel Advisors LLC raised its position in Edwards Lifesciences by 11.2% during the 4th quarter. Parallel Advisors LLC now owns 684 shares of the medical research company’s stock worth $101,000 after buying an additional 69 shares during the last quarter. Finally, BB&T Securities LLC raised its position in Edwards Lifesciences by 0.9% during the 4th quarter. BB&T Securities LLC now owns 8,179 shares of the medical research company’s stock worth $1,252,000 after buying an additional 70 shares during the last quarter. Institutional investors own 84.87% of the company’s stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic valve replacement, and transcatheter mitral and tricuspid therapies for the nonsurgical replacement of heart valves.

Featured Story: How to find the components of the quick ratio

Earnings History and Estimates for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.